Study on material basis and pharmacodynamic mechanism of heat-clearing and damp-eliminating Ermiao Powder based on chinmedomics

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055467

Enrollment

Unknown

Registered

2022-01-10

Start date

2021-12-10

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gouty arthritis

Interventions

Heathy group (no randomization):None

Gout patients control group:None

Ermiao powder group:Ermiao Powder Granule

Sanmiao powder group:Sanmiao Powder Granule

Simiao powder group:Simiao Powder Granule

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Healthy people: (1) Aged between 18 and 70 years; (2) Subjects or their family members (guardians) agree to participate in this study and sign the informed consent. 2. Patients with gouty arthritis: (1) The research subjects meet the 2015 ACR/EULAR diagnostic criteria for gouty arthritis; (2) Subjects who meet the diagnostic criteria of Traditional Chinese Medicine Dampness Syndrome’’ of the National Key Laboratory of TCM Dampness Syndrome jointly established by the province and the ministry, and are accompanied by lower extremity arthritis, redness, swelling, heat and pain; (3) Aged between 18 and 70 years; (4) Written informed consent signed by the subjects or their family members (guardians) to participate in this trial.

Exclusion criteria

Exclusion criteria: 1. Healthy people: (1) Patients with hyperuricemia or gouty arthritis; (2) Patients with severe cardiovascular, brain, lung, liver, kidney, gastrointestinal, hematopoietic system diseases, malignant tumors and mental diseases; (3) Pregnancy or lactation. 2. Patients with gouty arthritis: (1) Patients with severe cardiovascular, brain, lung, liver, kidney, hematopoietic system diseases, malignant tumors and mental diseases; (2) Pregnant or breastfeeding; (3) Patients with active gastroduodenal ulcer or gastritis caused by long-term use of non-steroidal anti-inflammatory drugs; (4) Patients with secondary gout caused by underlying diseases or the use of drugs (such as aspirin, cyclosporine, diuretics, etc.).

Design outcomes

Primary

Measure	Time frame
uric acid;	—

Secondary

Measure	Time frame
ESR;C-reactive protein;the number of the affected joint and gouty tophus;visual analogue scale;wet syndrome assessment;	—

Countries

China

Contacts

Public ContactHuang Runyue

ryhuang@gzucm.edu.cn+86 15889932190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026